All In Biotech

Drug Trial Radar · NCT06400459

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Phase 1/2a, Proof-of-Concept, Multicenter, Parallel, Vehicle-Controlled, Double-Masked, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of IVW-1001 Ophthalmic Eyelid Wipe in Subjects With Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Jun 25, 2024

Primary completion

Oct 15, 2024

Study completion Oct 15, 2024

Sponsor

Lead sponsor
IVIEW Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.

Conditions

  • Dry Eye Disease

Interventions

  • IVW-1001 Ophthalmic Eyelid Wipe 0.1%Drug

    IVW-1001 Ophthalmic Eyelid Wipe 0.1%

  • IVW-1001 Ophthalmic Eyelid Wipe 0.2%Drug

    IVW-1001 Ophthalmic Eyelid Wipe 0.2%

  • IVW-1001 PlaceboDrug

    IVW-1001 Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Schirmer'sTime frame: 29 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Houston Eye Associates

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.